Table 4 Incremental cost-effectiveness ratios (dosage 40 mg/kg/week unless otherwise specified)
Costs/QALY gained | Costs/life year gained | |
|---|---|---|
Base case analysis dosage 40 mg/kg/week | € 1,043,868 | € 525,873 |
Registered dosage regimen (20 mg/kg/2 weeks) | € 286,114 | € 144,137 |
Lower treatment costs (costs divided by 2) | € 549,280 | € 276,713 |
Shorter time horizon (5 years) | € 571,701 | € 92,634 |
Lower utility (0.49) in both cohorts | € 1,304,835 | € 525,873 |
Higher utility (0.74) in both cohorts | € 869,890 | € 525,873 |
Lower utility in ST-treated patients | € 1,021,610 | € 525,873 |
Lognormal survival distribution | € 1,050,595 | € 452,669 |
No costs incurred by ST-treated patients | € 1,049,203 | € 528,560 |
Double cost incurred by ST-treated patients | € 1,031,836 | € 520,387 |